The latest update on the Natpar shortages from Takeda are as follows:
- 100mcg dose – shortage duration is now unknown but is expected to last at least 6 months.
75mcg dose – shortage expected later in 2022
In response to your questions we can now tell you that :
- MHRA have sent information regarding latest treatment management to healthcare professionals (HCPs). Ask your endocrinologist about this if you haven’t already spoken to them.
- Existing patients will have priority regarding continued access to Natpar. However, Takeda will support new patients if their endocrinologist considers it necessary.
- Supply of Natpar in the USA and Europe are linked to manufacturing issues but for different reasons. In the USA there was a problem with rubber particles and in Europe the issue is with protein particles. However, ongoing rigorous testing ensures that current doses are safe.
We will keep you informed of any further updates.